Nanosphere’s Verigene BC-GP Decreases Patient Length of Stay

NORTHBROOK, Ill., March 03, 2016 -- Nanosphere, Inc. (NASDAQ:NSPH), a company enhancing medicine through targeted molecular diagnostics, today announced publication of a study that demonstrates the clinical and economic impact of implementing rapid sepsis diagnostic testing with the Company’s FDA-cleared Verigene® Gram-Positive Blood Culture Test (BC-GP) in a pediatric patient population.

The pre-post outcomes study was conducted at Children’s Hospital Los Angeles in Los Angeles, California and published in the peer-reviewed journal Archives of Pathology & Lab Medicine.

“Our study is the first to assess the clinical and economic impact of BC-GP in a pediatric population,” said Jennifer Dien Bard, Ph.D., D (ABMM), FCCM, Director of the Clinical Microbiology Laboratory at Children’s Hospital Los Angeles. “We saw a decrease in morbidity, mortality, length of stay, and hospital costs for pediatric patients with gram-positive bloodstream infections after implementing BC-GP.”

The statistically significant results of the study included:

• 5.6-day median length-of-stay reduction for patients with S. aureus bloodstream infections (8.9 versus 14.7 days)
• 1.9-day overall median hospital length-of-stay reduction per patient (7.2 versus 9.1 days)
• 39.6-hour reduction in antimicrobial exposure for patients with contaminated blood cultures (28.1 versus 67.7 hours)
• 12.5-hour reduction in overall time to antimicrobial optimization (34.1 versus 46.6 hours)

“The findings from this study illustrate the profound impact the Verigene System can have on the care and outcomes for one of the highest risk patient populations,” said Michael McGarrity, Nanosphere’s president and chief executive officer.

Contributors to the manuscript, “Impact of a Rapid Blood Culture Assay for Gram-Positive Identification and Detection of Resistance Markers in a Pediatric Hospital,” include Susanna Felsenstein, Jeffrey Bender, Matthew Gentry, Carol Takemoto, and Jennifer Dien Bard.

About Nanosphere, Inc.
Nanosphere is enhancing medicine through targeted molecular diagnostics that result in earlier disease detection, optimal patient treatment and improved healthcare economics. The Company’s versatile technology platform, the Verigene® System, enables clinicians to rapidly detect the most complex, costly and deadly infectious diseases through a low cost and simple-to-use multiplexed diagnostic test. The combination of this innovative technology and Nanosphere’s customer-driven solutions keeps commitment to the patient at the forefront of its business. Nanosphere is based in Northbrook, IL. Additional information is available at http://www.nanosphere.us.

About Archives of Pathology & Laboratory Medicine
The Archives of Pathology & Laboratory Medicine is published monthly by the College of American Pathologists, and is an official publication of the College of American Pathologists. The College of American Pathologists, the leading organization of board-certified pathologists, serves patients, pathologists, and the public by fostering and advocating excellence in the practice of pathology and laboratory medicine worldwide. Studies show that The Archives of Pathology & Laboratory Medicine is the most highly read journal/periodical title among US practicing pathologists. 

Except for historical information, the matters discussed in this press release are “forward-looking statements” and are subject to risks and uncertainties. Actual results could differ materially from these forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, the following: (i) Nanosphere’s ability to develop commercially viable products; (ii) Nanosphere’s ability to achieve profitability; (iii) Nanosphere’s ability to produce and market its products; (iv) Nanosphere’s ability to obtain regulatory approval of its products; (v) Nanosphere’s ability to protect its intellectual property; (vi) competition and alternative technologies; and (vii) Nanosphere’s ability to obtain additional financing to support its operations. Additional risks are discussed in the Company’s current filings with the Securities and Exchange Commission. Although the Company believes the expectations reflected in such forward-looking statements are based on reasonable assumptions, it can give no assurance that its expectations will be attained. The forward-looking statements are made as of the date of this press release, and we undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

CONTACTS
Investors:
Michael Rice, LifeSci Advisors
646-597-6979
[email protected]

Media:
Zachary Crowther, Director of Marketing
847-400-9047
[email protected]